Dr Reddy's Lab Ltd Adr: (NYSE: RDY)

$36.79

-0.87 (-2.31%)

Volume 50,425

May 21 09:54 AM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		36.54 - 36.97
	
		52wk Low - High
		27.28 - 38.74
	
		Previous Close
		37.66
	
		Avg. Volume
		201,586
	
		Industry
		MED-GENERIC DRG
	
		Market Cap
		6.39 B
	
		Div - Yield
		0.23 - 0.60
	
		Beta
		1.06
	
		PE (Forward)
		18.37
	
		Current Year Est.
		2.05
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		235 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/15/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            18.37
                        
                            PEG Ratio
                            1.22
                        
                            Current Year Est.
                            2.05
                        
                            Current Quarter Estimate
                            NA
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            07-18-2013
                        
                            EPS Last Year
                            1.95
                        
                            Expected Earnings Growth
                            15.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection   
Full RDY Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
RDY Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (03/2014)	Next Year (03/2015)
Average Estimate	NA	NA	2.05	2.25
Number of Estimates	0	0	2	1
Low Estimate	NA	NA	2.03	2.25
High Estimate	NA	NA	2.07	NA
Year Ago EPS	0.37	0.58	1.85	2.05
EPS Growth	NA	NA	10.81%	9.76%

More RDY Estimates

Average Earnings Estimates for RDY

EPS Growth for RDY

Industry Analysis

Name	Symbol	Previous Close
DOCTOR REDDYS	RDY	37.66
ACTAVIS INC	ACT	127.15
ACURA PHARMACT	ACUR	2.40
HI TECH PHARMA	HITK	32.95
IMPAX LABORATRS	IPXL	18.43
KALOBIOS PHARMA	KBIO	5.80
MYLAN INC	MYL	31.28
OMTHERA PHARMA	OMTH	6.86
SIMCERE PHARMAC	SCR	9.29
SUPERNUS PHARMA	SUPN	6.26

Sector:Medical>> Industry:MED-GENERIC DRG

COMPARE TICKER vs. Its Peers

Zacks Commentary

Dr. Reddy's Earnings Increase Y/Y

May 15, 2013

Earnings Miss at Perrigo

May 07, 2013

Perrigo Likely to Report In Line Earnings

May 06, 2013

Mylan Reports in line Earnings

May 03, 2013

Still Neutral on Mylan

Apr 15, 2013

Dr. Reddy's Launches Generic Reclast

Apr 04, 2013

Another Generic Launch at Mylan

Apr 04, 2013

Dr. Reddy's Launches Generic Accutane

Apr 01, 2013

More RDY Zacks Commentary

Financials

EPS TTM	1.95
Sales	2,133
Net Income	311
Price/Earnings	19.31
Price/Book	4.75
Price/Cash Flow	15.88
Price/Sales	2.99

More RDY Financials

News

Shares of Dr Reddys Laboratories Under Pressure, Down 1.6% - Financial News Network Online - Market Movers

May 17, 2013

Watch for Continued Gains in Shares of Dr Reddys Laboratories (RDY) - Financial News Netwfork Online - 52-Week High-Lows

May 16, 2013

Dr. Reddy`s Laboratories Beats on Both Top and Bottom Lines - TheMotleyFool

May 15, 2013

Dr. Reddy's Laboratories Ltd.Corporate Event Announcement Notice - Wall Street Horizon

May 14, 2013

Dr. Reddy's Q4 & FY13 Financial Results - Businesswire

May 14, 2013

Shares of Dr Reddys Laboratories Under Pressure, Down 2.3% - Financial News Network Online - Market Movers

May 14, 2013

Bullish Moving Average Cross by Dr Reddys Laboratories (RDY) - Financial News Network Online - Moving Average Crossovers

May 10, 2013

Stock Investors Bid Up Shares of Dr Reddys Laboratories, Up 1.9% - Financial News Network Online - Market Movers

May 10, 2013

See All News Stories on RDY

Broker Recommendations

Current ABR	2.33
ABR (Last Week)	2.33
# of recs in ABR	3
Average Target Price	38.50
Industry Rank by ABR	235 out of 265
Rank in Industry	10 out of 13

More RDY Broker Recommendations

Day Low - High	36.54 - 36.97
52wk Low - High	27.28 - 38.74
Previous Close	37.66
Avg. Volume	201,586
Industry	MED-GENERIC DRG
Market Cap	6.39 B
Div - Yield	0.23 - 0.60
Beta	1.06
PE (Forward)	18.37
Current Year Est.	2.05
Quarterly Earnings ESP	NA

PE (Forward)	18.37
PEG Ratio	1.22
Current Year Est.	2.05
Current Quarter Estimate	NA
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	07-18-2013
EPS Last Year	1.95
Expected Earnings Growth	15.00%

Username: Password:

Remember me [?]

Dr Reddy's Lab Ltd Adr: (NYSE: RDY)

$36.79

-0.87 (-2.31%)

Volume 50,425

May 21 09:54 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-GENERIC DRG

Zacks Commentary

Financials

News

Broker Recommendations